This review argues that may have neuroprotective potential across several neurological disorders.
Evidence
It synthesizes preclinical and clinical evidence on GLP-1 receptor agonists in disorders including Alzheimer's disease, Parkinson's disease, stroke, multiple sclerosis, ALS, depression, epilepsy, and spinal cord injury.
Caveat
Clinical results remain mixed, and differences in penetration across GLP-1 receptor agonists may limit translation.
Simplified
Glucagon-like peptide-1 receptor agonists, or GLP-1RAs, have been used for years to treat type 2 diabetes and obesity. More recently, it has become clear that these receptors are widely distributed throughout the central nervous system (CNS), which has raised the possibility of repurposing these drugs for neurological disorders. In this review we go through the evidence across a range of neurological conditions, discuss the main mechanisms thought to explain their neuroprotective effects, and point out the hurdles that still need to be cleared before they can be used in the clinic. Preclinical work has been fairly consistent. These drugs activate the cAMP/PKA/CREB pathway to boost BDNF expression. They also turn on the PI3K/Akt pathway, which reins in GSK-3β and cuts down tau hyperphosphorylation. At the same time, they put the brakes on NLRP3 inflammasome activation in microglia and get AMPK dependent mitochondrial biogenesis and autophagy going. In animal models of Alzheimer's disease (AD), Parkinson's disease (PD), ischemic stroke, intracerebral hemorrhage (ICH), Huntington's disease (HD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), depression, epilepsy, and spinal cord injury (SCI), these cellular changes add up to less protein aggregation, less neuron loss, and better functional outcomes. Clinical data are harder to interpret. Some trials have shown modest improvements in cognition or motor function, but others have found no meaningful effect on disease progression. One thing that does not get enough attention is that different cross the at widely varying rates, and these differences could well explain why trial results have been so mixed. Looking ahead, getting these drugs into the clinic will depend on choosing the ones that actually reach the CNS, developing biomarkers that can predict who will respond, and designing trials that take disease heterogeneity into account. Seen this way, this review offers a practical framework for turning mechanistic insights into real patient benefit.
Key numbers
131.5 million
Projected Alzheimer's Disease Cases
Expected number of people living with dementia by 2050.
10 million
10 million
Number of people affected by Parkinson's disease worldwide.
3.5-point
3.5-point improvement
Reported improvement on the MDS UPDRS Part III in the phase 2 Exenatide PD2 trial.
Full Text
We can’t show the full text here under this license.
